Search Results - "Moroni, Dante"
-
1
Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation
Published in International journal of molecular sciences (10-05-2023)“…The natriuretic peptide system (NPS) and renin-angiotensin-aldosterone system (RAAS) function oppositely at multiple levels. While it has long been suspected…”
Get full text
Journal Article -
2
Discovery of small molecule guanylyl cyclase B receptor positive allosteric modulators
Published in PNAS nexus (01-06-2024)“…Myocardial fibrosis is a pathological hallmark of cardiovascular disease (CVD), and excessive fibrosis can lead to new-onset heart failure and increased…”
Get full text
Journal Article -
3
-
4
Abstract 4140511: Synergistic insulinotropic and lipolytic actions of GLP-1 and a novel miniaturized designer GC-A peptide activator in Beta cells and adipocytes: Potential therapeutic insights for cardiometabolic disease
Published in Circulation (New York, N.Y.) (12-11-2024)“…Abstract only BACKGROUND: Atrial natriuretic peptide (ANP) and glucagon-like peptide-1 (GLP-1) are endogenous hormones known for roles in cardiovascular…”
Get full text
Journal Article -
5
Abstract 4141935: Targeting Tyrosine Kinase Inhibitor-Associated Cardiotoxicity with NPA7: A Novel Dual Activating Peptide
Published in Circulation (New York, N.Y.) (12-11-2024)“…Abstract only Background: Tyrosine kinase inhibitors (TKIs), such as sunitinib, are highly effective in treating cancers. However, they have severe…”
Get full text
Journal Article -
6
CARDIAC APOPTOSIS IS INCREASED IN A RODENT MODEL OF EARLY NON-ALCOHOLIC FATTY LIVER DISEASE
Published in Journal of the American College of Cardiology (02-04-2024)Get full text
Journal Article -
7
Abstract 14638: NPA7: A Novel Designed Bispecific Peptide That Protects Human Cardiomyocytes Against Oxidative Stress Through the GC-A/Mas Receptor-KEAP1-NRF2 Pathway
Published in Circulation (New York, N.Y.) (07-11-2023)“…Abstract only Introduction: Excess cardiomyocyte oxidative stress is a major metabolic abnormality in HTN and its progression to HF. Thus, therapies that…”
Get full text
Journal Article -
8
CRRL191: A NOVEL BIOENGINEERED PEPTIDE ACTIVATOR OF THE GUANYLYL CYCLASE A RECEPTOR THAT HAS MORE POTENT AND LONG-LASTING BLOOD PRESSURE LOWERING AND RENAL ENHANCING ACTIONS THAN ATRIAL NATRIURETIC PEPTIDE
Published in Journal of the American College of Cardiology (07-03-2023)Get full text
Journal Article -
9
Abstract 11943: MCUF-651: A Novel Natriuretic Peptide Receptor A (NPRA) Small Molecule Positive Allosteric Modulator With Blood Pressure Lowering and Renal Enhancing Properties in Experimental Hypertension
Published in Circulation (New York, N.Y.) (08-11-2022)“…IntroductionHypertension (HTN) represents one of the greatest burdens in human health and is associated with increased morbidity and mortality. Despite the…”
Get full text
Journal Article -
10
Abstract 13473: Impaired Atrial Natriuretic Peptide Potency in Human Acute Decompensated Heart Failure and Therapeutic Potential of a Novel Designer Peptide (MANP) Using an Innovative Ex-Vivo Precision Medicine Assay
Published in Circulation (New York, N.Y.) (08-11-2022)“…IntroductionAtrial natriuretic peptide (ANP) is the most potent endogenous activator of the guanylyl cyclase A receptor (GC-A) mediating cardiorenal protective…”
Get full text
Journal Article